Formation of a N2-dG:N2-dG carbinolamine DNA cross-link by the trans-4-hydroxynonenal-derived (6S,8R,11S) 1,N2-dG adduct. Huang H, Wang H, Kozekova A, Rizzo CJ, Stone MP (2011) J Am Chem Soc 133: 16101-10 Apoptotic response of HL-60 human leukemia cells to the antitumor drug TAS-103. Kluza J, Lansiaux A, Wattez N, Mahieu C, Osheroff N, Bailly C (2000) Cancer Res 60: 4077-84 The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I. Gentry AC, Juul S, Veigaard C, Knudsen BR, Osheroff N (2011) Nucleic Acids Res 39: 1014-22 Real-time imaging of the reorientation mechanisms of YOYO-labelled DNA molecules during 90 degrees and 120 degrees pulsed field gel electrophoresis. Gurrieri S, Smith SB, Wells KS, Johnson ID, Bustamante C (1996) Nucleic Acids Res 24: 4759-67 Biological characterization of MLN944: a potent DNA binding agent. Sappal DS, McClendon AK, Fleming JA, Thoroddsen V, Connolly K, Reimer C, Blackman RK, Bulawa CE, Osheroff N, Charlton P, Rudolph-Owen LA (2004) Mol Cancer Ther 3: 47-58 Base-Displaced Intercalated Conformation of the 2-Amino-3-methylimidazo[4,5-f]quinoline N(2)-dG DNA Adduct Positioned at the Nonreiterated G(1) in the NarI Restriction Site. Stavros KM, Hawkins EK, Rizzo CJ, Stone MP (2015) Chem Res Toxicol 28: 1455-68 3'-Intercalation of a N2-dG 1R-trans-anti-benzo[c]phenanthrene DNA adduct in an iterated (CG)3 repeat. Wang Y, Schnetz-Boutaud NC, Kroth H, Yagi H, Sayer JM, Kumar S, Jerina DM, Stone MP (2008) Chem Res Toxicol 21: 1348-58 Conformational differences of the C8-deoxyguanosine adduct of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) within the NarI recognition sequence. Elmquist CE, Wang F, Stover JS, Stone MP, Rizzo CJ (2007) Chem Res Toxicol 20: 445-54 Wobble dC.dA pairing 5' to the cationic guanine N7 8,9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B1 adduct: implications for nontargeted AFB1 mutagenesis. Giri I, Stone MP (2003) Biochemistry 42: 7023-34 Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions. Ketron AC, Denny WA, Graves DE, Osheroff N (2012) Biochemistry 51: 1730-9 Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine. Cline SD, Macdonald TL, Osheroff N (1997) Biochemistry 36: 13095-101 The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs. McClendon AK, Osheroff N (2006) Biochemistry 45: 3040-50 Mispairing of the 8,9-dihydro-8-(N7-guanyl)-9-hydroxy-aflatoxin B1 adduct with deoxyadenosine results in extrusion of the mismatched dA toward the major groove. Giri I, Johnston DS, Stone MP (2002) Biochemistry 41: 5462-72 Minor groove orientation for the (1S,2R,3S,4R)-N2- [1-(1,2,3,4-tetrahydro-2,3,4-trihydroxybenz[a]anthracenyl)]-2'-deoxyguanosyl adduct in the N-ras codon 12 sequence. Kim HY, Wilkinson AS, Harris CM, Harris TM, Stone MP (2003) Biochemistry 42: 2328-38 Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage. Marx G, Zhou H, Graves DE, Osheroff N (1997) Biochemistry 36: 15884-91 DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition. Fortune JM, Velea L, Graves DE, Utsugi T, Yamada Y, Osheroff N (1999) Biochemistry 38: 15580-6 DNA abasic lesions in a different light: solution structure of an endogenous topoisomerase II poison. Cline SD, Jones WR, Stone MP, Osheroff N (1999) Biochemistry 38: 15500-7
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.